AmMax Bio, Inc.: Clinical Trials

6 trials sponsored by AmMax Bio, Inc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated, 1 withdrawn. 5 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 3, Terminated 1, Withdrawn 1
Phase 12Completed 2

Follow AmMax Bio, Inc.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis
AMB-05X, Placebo - IPF
Phase 2WithdrawnAmMax Bio, Inc.2023-03-012023-01-19
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
AMB-05X - Pigmented Villonodular Synovitis, TGCT
Phase 2CompletedAmMax Bio, Inc.202023-01-262024-07-05
A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients
AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis
Phase 2TerminatedAmMax Bio, Inc.42021-09-162024-05-24
An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee
AMB-05X - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS)
Phase 2CompletedAmMax Bio, Inc.112021-05-252024-06-27
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
AMG820 and pembrolizumab - Pancreatic Cancer, Colorectal Cancer
Phase 1 / Phase 2CompletedAmMax Bio, Inc.1172016-04-142023-01-20
A Study of AMG 820 in Subjects With Advanced Solid Tumors
AMG 820 - Advanced Malignancy, Advanced Solid Tumors
Phase 1CompletedAmMax Bio, Inc.252008-03-312023-01-19

Conditions studied

Giant Cell Tumor of Tendon Sheath (3)  ·  Synovitis, Pigmented Villonodular (3)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Idiopathic Pulmonary Fibrosis (1)  ·  Neoplasms (1)  ·  Pancreatic Neoplasms (1)

Interventions

pembrolizumab (1)

Countries

United States (4)  ·  Australia (2)  ·  Netherlands (2)  ·  Poland (2)  ·  Ukraine (2)  ·  Belgium (1)  ·  Canada (1)  ·  Germany (1)  ·  Hungary (1)  ·  Spain (1)

Top investigators

Dorothy Nguyen, MD (4)

NIH funding

2016 (1)